Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 77

Results For "S-1"

939 News Found

Healthcare for seniors an opportunity for service providers
Public Health | January 19, 2022

Healthcare for seniors an opportunity for service providers

Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas


Strides receives USFDA approval for influenza medicine
Drug Approval | January 17, 2022

Strides receives USFDA approval for influenza medicine

The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval


Glenmark receives U.S. FDA approval for Ryaltris
Drug Approval | January 14, 2022

Glenmark receives U.S. FDA approval for Ryaltris

The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily


Metropolis Healthcare opens MedEngage Scholarship programme
News | January 13, 2022

Metropolis Healthcare opens MedEngage Scholarship programme

The last date to apply for this program is 18th January 2022


South Korea approves Novavax Covid-19 vaccine
Drug Approval | January 13, 2022

South Korea approves Novavax Covid-19 vaccine

Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea


Normalised quarter with impending margin pressure: ICICI Direct
News | January 13, 2022

Normalised quarter with impending margin pressure: ICICI Direct

ICICI Direct gives a preview on the earnings narrative for Q3FY22


Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’
Sustainability | January 13, 2022

Cipla wins Frost & Sullivan and Teri Sustainability award for `Challenger in Mega Large Business Pharma Sector’

The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Odisha is the first state to place order for OmiSure to detect Omicron
Medical Device | January 10, 2022

Odisha is the first state to place order for OmiSure to detect Omicron

TATA MD’s OmiSure is the only test approved by the ICMR for RT-PCR detection of the Omicron variant